These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26254386)

  • 1. Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation.
    Niibe Y; Yamashita H; Sekiguchi K; Takahashi W; Shiraishi K; Okuma K; Terahara A; Kawamori J; Nakagawa K
    Anticancer Res; 2015 Sep; 35(9):4903-8. PubMed ID: 26254386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases.
    Yamashita H; Niibe Y; Yamamoto T; Katsui K; Jingu K; Kanazawa S; Terahara A; Nakagawa K
    Jpn J Clin Oncol; 2016 Jul; 46(7):687-91. PubMed ID: 27162324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
    Niibe Y; Yamamoto T; Onishi H; Yamashita H; Katsui K; Matsumoto Y; Oh RJ; Aoki M; Shintani T; Yamada K; Kobayashi M; Ozaki M; Manabe Y; Yahara K; Nishikawa A; Kakuhara H; Yamamoto K; Inoue T; Takada YU; Nagata K; Suzuki O; Terahara A; Jingu K
    Anticancer Res; 2020 Jan; 40(1):393-399. PubMed ID: 31892592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    Yamamoto T; Niibe Y; Aoki M; Shintani T; Yamada K; Kobayashi M; Yamashita H; Ozaki M; Manabe Y; Onishi H; Yahara K; Nishikawa A; Katsui K; Oh RJ; Terahara A; Jingu K
    BMC Cancer; 2020 Oct; 20(1):997. PubMed ID: 33054721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Jingu K; Matsuo Y; Onishi H; Yamamoto T; Aoki M; Murakami Y; Yamashita H; Kakuhara H; Nemoto K; Sakayauchi T; Okamoto M; Niibe Y; Nagata Y; Ogawa K
    Anticancer Res; 2017 May; 37(5):2709-2713. PubMed ID: 28476849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study.
    Aoki M; Hatayama Y; Kawaguchi H; Hirose K; Sato M; Akimoto H; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Jan; 57(1):55-61. PubMed ID: 26494115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
    Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
    BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors.
    Yamamoto T; Niibe Y; Matsumoto Y; Dekura Y; Oh RJ; Yamashita H; Kakuhara H; Aoki M; Jingu K
    Anticancer Res; 2020 Apr; 40(4):2065-2072. PubMed ID: 32234898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results.
    Carvajal C; Navarro-Martin A; Cacicedo J; Ramos R; Guedea F
    J BUON; 2015; 20(1):158-65. PubMed ID: 25778311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases.
    Yamamoto T; Niibe Y; Matsumoto Y; Aoki M; Oh RJ; Ozaki M; Kobayashi M; Manabe Y; Shintani T; Dekura Y; Onishi H; Yamashita H; Jingu K
    Cancer Med; 2020 Dec; 9(23):8902-8911. PubMed ID: 33022899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.
    Takeda A; Sanuki N; Tsurugai Y; Oku Y; Aoki Y
    J Radiat Res; 2016 Jul; 57(4):400-5. PubMed ID: 26983981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Pasqualetti F; Montrone S; Vivaldi C; Zani M; Fedele D; Fornaro L; Pasqualetti G; Salvatore L; Manfredi B; Laliscia C; Coraggio G; Gonnelli A; Loupakis F; Masi G; Sainato A; Monzani F; Falcone A; Paiar F
    Anticancer Res; 2017 Jan; 37(1):315-319. PubMed ID: 28011508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study.
    Nuyttens JJ; van der Voort van Zyp NC; Verhoef C; Maat A; van Klaveren RJ; van der Holt B; Aerts J; Hoogeman M
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):337-43. PubMed ID: 25636758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases.
    Osti MF; Carnevale A; Valeriani M; De Sanctis V; Minniti G; Cortesi E; Martelli M; Maurizi Enrici R
    Clin Lung Cancer; 2013 Nov; 14(6):699-703. PubMed ID: 23886798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.